Leukemia: all 5,475 studies
Page 32 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)Status unknownNCT02717884Phase 1/2
- Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT02715011Phase 1
- Prognostic Role of Minimal Residual Disease in Acute Myeloid LeukemiaCompletedNCT02714790
- A Clinical Research of CD20-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT02710149Phase 1/2
- Decitabine for Chemotherapy Unfit Korean AML Patients in Real PracticeStatus unknownNCT02698124
- Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute LeukemiaCompletedNCT02693899
- Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia PatientsStatus unknownNCT02690922Phase 4
- Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)CompletedNCT02689141Phase 2
- Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous LeukemiaStatus unknownNCT02687425Phase 2
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid LeukemiaStatus unknownNCT02682732Not applicable
- Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaWithdrawnNCT02680951Phase 1
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
- Hematopoietic Stem Cell Microtransplantation for in AMLStatus unknownNCT02676856Not applicable
- Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT02676323Phase 1
- Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid LeukemiaCompletedNCT02674763Phase 1
- A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell LeukemiaStatus unknownNCT02672501Phase 1/2
- IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCTCompletedNCT02671708Phase 2/3
- BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCTCompletedNCT02670252Phase 3
- A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyCompletedNCT02670044Phase 1
- Samples From Leukemia Patients and Their Donors to Identify Specific AntigensStatus unknownNCT02667093
- Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT02665065Phase 3
- Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)CompletedNCT02662933Not applicable
- Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)CompletedNCT02662920
- Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALLStatus unknownNCT02660762Phase 2
- LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02652871Phase 1
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
- Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or OlderWithdrawnNCT02647190Phase 1
- Pre-existing Kinase Domain Mutations in Ph-positive LeukemiasStatus unknownNCT02643888
- Improving Patient Education for Lymphoma and Leukemia InpatientsCompletedNCT02642510Not applicable
- A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT02641002Phase 1
- A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
- Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)TerminatedNCT02640209Early Phase 1
- Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs TherapyCompletedNCT02638467Phase 2
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02635074Phase 1
- Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot StudyWithdrawnNCT02632903Phase 2
- Photochemotherapy and Graft-versus-leukemia in Acute-leukemiaCompletedNCT02631993
- Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous LeukemiaTerminatedNCT02631252Phase 1
- Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCTTerminatedNCT02627573Phase 2
- Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation ChemotherapyNo longer availableNCT02624570
- CD123 Redirected Autologous T Cells for AMLTerminatedNCT02623582Early Phase 1
- A Quality Improvement Approach to the Management of Chronic Lymphocytic LeukemiaCompletedNCT02619604Not applicable
- ChEmo-Genomics Based Treatment of Acute Myeloid LeukemiaStatus unknownNCT02619071Not applicable
- Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic LeukemiaTerminatedNCT02618109Phase 4
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
- Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.WithdrawnNCT02611908Phase 1
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02610062Phase 1
- VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 YearsCompletedNCT02606825
- Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete RemissionStatus unknownNCT02605460Phase 2
- Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia PatientsCompletedNCT02602587Not applicable
- Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
- Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell TransplantationCompletedNCT02598752
- Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT02588456Phase 1
- Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in RemissionWithdrawnNCT02587871Phase 2
- Physical Activity as Self-Management Approach to Improve Health Outcomes in AMLCompletedNCT02584296Not applicable
- informCLL™: A Disease Registry for Patients With Chronic Lymphocytic LeukemiaCompletedNCT02582879
- MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of AgeCompletedNCT02582359Phase 1
- Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient ProgramCompletedNCT02582320
- Metabolic Changes in Blood Samples From Patients With Acute Myeloid LeukemiaCompletedNCT02581917
- Acute Lymphoblastic Leukemia Therapies Informed by Genomic AnalysesTerminatedNCT02580981Not applicable
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 1
- Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia PatientsCompletedNCT02580071Not applicable
- Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)WithdrawnNCT02578511Phase 1
- Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02573363Phase 1
- Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic MalignanciesCompletedNCT02566395Phase 3
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
- A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02556892Phase 1
- Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT02556346Phase 1
- Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia PatientsCompletedNCT02553304
- A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML PatientsCompletedNCT02550535Phase 1/2
- Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter StudyCompletedNCT02546791
- Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT02546284Phase 1
- Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic LeukemiaCompletedNCT02544789Phase 2
- Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT02544438Phase 1/2
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
- DC Vaccination in CMLTerminatedNCT02543749Phase 1/2
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedNCT02535286Phase 1
- Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
- CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)CompletedNCT02527447
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid LeukemiaWithdrawnNCT02527174Phase 1
- Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2
- Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT02520895
- Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous LeukemiaWithdrawnNCT02520102Phase 2
- Leukemia Inhibitory Factor Level in Intrauterine Growth Restriction NeonatesStatus unknownNCT02518126
- Carfilzomib in Combination With Cyclophosphamide and Etoposide for ChildrenCompletedNCT02512926Phase 1
- A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknownNCT02511340Phase 2
- B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)Status unknownNCT02493829Phase 1
- Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaCompletedNCT02491398
- Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by AzacytidineStatus unknownNCT02489929Not applicable
- Allo-HSCT With Alternative Donor in Treatment of Hematologic MalignancyCompletedNCT02487069Not applicable
- Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After TransplantCompletedNCT02485535Phase 1
- Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in ChildrenTerminatedNCT02484261Phase 1
- Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDSTerminatedNCT02477787Phase 2